Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings Of The Fortnight Checks The Corporate Venture Numbers

This article was originally published in The Pink Sheet Daily

Executive Summary

Corporate venture investment is seen as increasingly important in life sciences finance. Plus news on recent financings by Retrophin, Sophiris Bio, Regado Biosciences and Tigercat Pharma.

You may also be interested in...

Shkreli’s Retrophin Gets Another Injection Of Capital; Talks Up Clinical Plans

The biotech, founded in late 2011 by venture capitalist Martin Shkreli, has yet to make any significant clinical moves with the compounds in its pipeline, but signs show that could change before year-end.

Hospitals, Insurers Enjoy Growing Influence As VCs

Over a decade ago, hospital companies began establishing venture capital funds to ride shotgun with institutional VCs, hoping to get a glimpse of health care’s future. Today, under health care reform, VC groups sponsored by providers and payors increasingly find themselves in the driver’s seat, looking for the start-ups that might have solutions to the industry’s biggest problem – cost.

Device Start-Ups Reap More Corporate Venture

Corporate VCs are increasingly becoming a stable supplier of capital to medical device companies. Corporate investors have been participating in a growing percentage of deals being done, according to Elsevier’s Strategic Transactions, and remain focused on later-stage rounds.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts